Phathom Pharmaceuticals, Inc. Capex/Depreciation

Capex/Depreciation of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex/Depreciation growth rates and interactive chart.

Highlights and Quick Summary

  • Capex/Depreciation for the quarter ending September 29, 2021 was -0.01 (a -94.21% decrease compared to previous quarter)
  • Year-over-year quarterly Capex/Depreciation decreased by -97.86%
  • Annual Capex/Depreciation for 2020 was -0.65 (a -98.92% decrease from previous year)
  • Twelve month Capex/Depreciation ending September 29, 2021 was -0.09 (a -67.9% decrease compared to previous quarter)
  • Twelve month trailing Capex/Depreciation decreased by -86.33% year-over-year
Trailing Capex/Depreciation for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-0.09 -0.28 -0.29 -0.65
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex/Depreciation of Phathom Pharmaceuticals, Inc.

Most recent Capex/Depreciationof PHAT including historical data for past 10 years.

Interactive Chart of Capex/Depreciation of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Capex/Depreciation for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.01 -0.1 -0.35
2020 -0.26 -0.41 -0.14 -2.69 -0.65
2019 -0.62 -0.16 -310.1 -60.55
2018 0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.